Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.

× No keyword cloud information.

14 in total

1. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Authors: Mark Levis; Farhad Ravandi; Eunice S Wang; Maria R Baer; Alexander Perl; Steven Coutre; Harry Erba; Robert K Stuart; Michele Baccarani; Larry D Cripe; Martin S Tallman; Giovanna Meloni; Lucy A Godley; Amelia A Langston; Sergio Amadori; Ian D Lewis; Arnon Nagler; Richard Stone; Karen Yee; Anjali Advani; Dan Douer; W Wiktor-Jedrzejczak; Gunnar Juliusson; Mark R Litzow; Stephen Petersdorf; Miguel Sanz; Hagop M Kantarjian; Takashi Sato; Lothar Tremmel; Debra M Bensen-Kennedy; Donald Small; B Douglas Smith
Journal: Blood Date: 2011-01-26 Impact factor: 22.113

2. Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.

Authors: Soheil Meshinchi; Stephen P Hunger; Richard Aplenc; Peter C Adamson; J Milburn Jessup
Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531

3. Treatment of FLT3-ITD acute myeloid leukemia.

Authors: Amir T Fathi; Yi-Bin Chen
Journal: Am J Blood Res Date: 2011-09-09

4. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

Authors: Amir T Fathi; Bruce A Chabner
Journal: Oncologist Date: 2011-07-17

Review 5. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.

Authors: Hillary Prescott; Hagop Kantarjian; Jorge Cortes; Farhad Ravandi
Journal: Expert Opin Emerg Drugs Date: 2011-03-22 Impact factor: 4.191

Review 6. Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.

Authors: Nathan Gossai; Rachel Cafferty; Brenda Weigel
Journal: Curr Treat Options Oncol Date: 2016-07

7. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Authors: Sarah L Sammons; Keith W Pratz; B Douglas Smith; Judith E Karp; Ashkan Emadi
Journal: Am J Hematol Date: 2014-06-23 Impact factor: 10.047

Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.